Additionally, the 36-month beta value for NRIX is 2.16. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 6 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for NRIX is 74.71M and currently, short sellers hold a 18.86% ratio of that float. The average trading volume of NRIX on June 13, 2025 was 1.01M shares.
NRIX) stock’s latest price update
The stock price of Nurix Therapeutics Inc (NASDAQ: NRIX) has dropped by -5.30 compared to previous close of 12.63. Despite this, the company has seen a fall of -4.32% in its stock price over the last five trading days. globenewswire.com reported 2025-06-12 that Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM
NRIX’s Market Performance
Nurix Therapeutics Inc (NRIX) has seen a -4.32% fall in stock performance for the week, with a 22.92% gain in the past month and a -9.33% plunge in the past quarter. The volatility ratio for the week is 3.04%, and the volatility levels for the past 30 days are at 4.07% for NRIX. The simple moving average for the past 20 days is 8.32% for NRIX’s stock, with a -33.94% simple moving average for the past 200 days.
Analysts’ Opinion of NRIX
Many brokerage firms have already submitted their reports for NRIX stocks, with Leerink Partners repeating the rating for NRIX by listing it as a “Market Perform.” The predicted price for NRIX in the upcoming period, according to Leerink Partners is $16 based on the research report published on March 17, 2025 of the current year 2025.
BTIG Research, on the other hand, stated in their research note that they expect to see NRIX reach a price target of $35. The rating they have provided for NRIX stocks is “Buy” according to the report published on December 10th, 2024.
BMO Capital Markets gave a rating of “Outperform” to NRIX, setting the target price at $35 in the report published on December 06th of the previous year.
NRIX Trading at 12.68% from the 50-Day Moving Average
After a stumble in the market that brought NRIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.54% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NRIX starting from van Houte Hans, who sale 6,198 shares at the price of $11.33 back on May 02 ’25. After this action, van Houte Hans now owns 33,724 shares of Nurix Therapeutics Inc, valued at $70,243 using the latest closing price.
JOHANNES VAN HOUTE, the Officer of Nurix Therapeutics Inc, proposed sale 6,198 shares at $11.16 during a trade that took place back on May 02 ’25, which means that JOHANNES VAN HOUTE is holding shares at $69,170 based on the most recent closing price.
Stock Fundamentals for NRIX
Current profitability levels for the company are sitting at:
- -4.09 for the present operating margin
- 0.78 for the gross margin
The net margin for Nurix Therapeutics Inc stands at -3.69. The total capital return value is set at -0.44. Equity return is now at value -64.16, with -44.93 for asset returns.
Based on Nurix Therapeutics Inc (NRIX), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -7.2.
Currently, EBITDA for the company is -196.6 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 15.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.26.
Conclusion
In conclusion, Nurix Therapeutics Inc (NRIX) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
